Video

Dr. Powles on the Impact of Immunotherapy in Kidney Cancer

Author(s):

Thomas Powles, MD

Thomas Powles, MD, Barts Cancer Institute, discusses the impact of immunotherapy on the treatment landscape of kidney cancer.

Thomas Powles, MD, Barts Cancer Institute, discusses the impact of immunotherapy on the treatment landscape of kidney cancer.

There has been an enormous change in the treatment of kidney cancer in 2017 with studies of immunotherapy in the frontline setting, says Powles.

CheckMate-214 is the study credited with potentially changing the frontline treatment of this disease, demonstrating a reduced risk of death of 32% with the combination on nivolumab (Opdivo) and ipilimumab (Yervoy) compared with sunitinib (Sutent).

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Brian I. Rini, MD, FASCO
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Related Content
Sonya Reid, MD, MPH
July 22nd 2024

Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Pedram Razavi, MD, PhD
July 22nd 2024

Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management

Neal Shore, MD, FACS
January 26th 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

Sara M. Tolaney, MD, MPH
July 20th 2024

De-Escalation Strategies, Biomarkers Could Refine Treatment Algorithm for Early-Stage HER2+ Breast Cancer

Hope S. Rugo, MD, of University of California, San Francisco
July 19th 2024

AE Management and Prevention Strategies for ADCs, Immunotherapy in Breast Cancer